TGF-β1 has been identified as a potential target for DN therapy, while the levels of α-SMA, a marker participating in the renal tubular epithelial-mesenchymal transition (EMT) process, are thought to reflect the degree of renal fibrosis [11, 12]. The gene discussed is ACTA1; the disease is liver dysplastic nodule.